» Articles » PMID: 27832188

Melatonin Receptor Agonists As the "Perioceutics" Agents for Periodontal Disease Through Modulation of Porphyromonas Gingivalis Virulence and Inflammatory Response

Overview
Journal PLoS One
Date 2016 Nov 11
PMID 27832188
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: "Perioceutics" including antimicrobial therapy and host modulatory therapy has emerged as a vital adjunctive treatment of periodontal disease. Melatonin level was significantly reduced in patients with periodontal diseases suggesting melatonin could be applied as a potential "perioceutics" treatment of periodontal diseases. This study aims to investigate the effects of melatonin receptor agonists (melatonin and ramelteon) on Porphyromonas gingivalis virulence and Porphyromonas gingivalis-derived lipopolysaccharide (Pg-LPS)-induced inflammation.

Methods: Effects of melatonin receptor agonists on Porphyromonas gingivalis planktonic cultures were determined by microplate dilution assays. Formation, reduction, and viability of Porphyromonas gingivalis biofilms were detected by crystal violet staining and MTT assays, respectively. Meanwhile, biofilms formation was also observed by confocal laser scanning microscopy (CLSM). The effects on gingipains and hemolytic activities of Porphyromonas gingivalis were evaluated using chromogenic peptides and sheep erythrocytes. The mRNA expression of virulence and iron/heme utilization was assessed using RT-PCR. In addition, cell viability of melatonin receptor agonists on human gingival fibroblasts (HGFs) was evaluated by MTT assays. After pretreatment of melatonin receptor agonists, HGFs were stimulated with Pg-LPS and then release of cytokines (IL-6 and lL-8) was measured by enzyme-linked immunosorbent assay (ELISA).

Results: Melatonin and ramelteon did exhibit antimicrobial effects against planktonic culture. Importantly, they inhibited biofilm formation, reduced the established biofilms, and decreased biofilm viability of Porphyromonas gingivalis. Furthermore, they at sub-minimum inhibitory concentration (sub-MIC) concentrations markedly inhibited the proteinase activities of gingipains and hemolysis in a dose-dependent manner. They at sub-MIC concentrations significantly inhibited the mRNA expression of virulence factors (kgp, rgpA, rgpB, hagA, and ragA), while increasing the mRNA expression of ferritin (ftn) or hemolysin (hem). They did not show obvious cytotoxicity toward HGFs. They inhibited Pg-LPS-induced IL-6 and IL-8 secretion, which was reversed by luzindole, the melatonin receptor antagonist.

Conclusion: Melatonin receptor agonists can inhibit planktonic and biofilm growth of Porphyromonas gingivalis by affecting the virulent properties, as well as Pg-LPS-induced inflammatory response. Our study provides new evidence that melatonin receptor agonists might be useful as novel "perioceutics" agents to prevent and treat Porphyromonas gingivalis-associated periodontal diseases.

Citing Articles

Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease.

Li H, Wen X, Gong X, Wu Y, Zhao P, Zhang Y Bioeng Transl Med. 2025; 10(2):e10730.

PMID: 40060759 PMC: 11883109. DOI: 10.1002/btm2.10730.


Evaluation of melatonin gel as local drug delivery system for the treatment of periodontitis: a split-mouth randomized controlled trial.

Pratap A, Srinath R, Praveen N, Sustarwar P, Sadarjoshi M, Almalki S BMC Oral Health. 2025; 25(1):230.

PMID: 39948592 PMC: 11827357. DOI: 10.1186/s12903-025-05598-y.


Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibiting .

Wang Y, Ma J, Wang H, Yi J, Bai Y, Hu M Front Microbiol. 2025; 16:1531258.

PMID: 39911249 PMC: 11794529. DOI: 10.3389/fmicb.2025.1531258.


Role of Melatonin in Periodontal Diseases: A Structured Review.

Khalid W, Koppolu P, Alhulaimi H, Alkhalaf A, Almajid A Adv Biomed Res. 2024; 13:88.

PMID: 39512417 PMC: 11542701. DOI: 10.4103/abr.abr_152_23.


An unidentified yet notable modification on and caused by ramelteon.

Wu P, Tu Y, Cho H, Yu M, Wu Y, Wu S FASEB Bioadv. 2024; 6(10):442-453.

PMID: 39372128 PMC: 11452446. DOI: 10.1096/fba.2024-00008.


References
1.
Saito T, Inagaki S, Sakurai K, Okuda K, Ishihara K . Exposure of P. gingivalis to noradrenaline reduces bacterial growth and elevates ArgX protease activity. Arch Oral Biol. 2010; 56(3):244-50. DOI: 10.1016/j.archoralbio.2010.09.014. View

2.
Tekbas O, Ogur R, Korkmaz A, Kilic A, Reiter R . Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule. J Pineal Res. 2008; 44(2):222-6. DOI: 10.1111/j.1600-079X.2007.00516.x. View

3.
Vanterpool E, Roy F, Fletcher H . The vimE gene downstream of vimA is independently expressed and is involved in modulating proteolytic activity in Porphyromonas gingivalis W83. Infect Immun. 2004; 72(10):5555-64. PMC: 517529. DOI: 10.1128/IAI.72.10.5555-5564.2004. View

4.
Elmahallawy E, Jimenez-Aranda A, Sampedro Martinez A, Rodriguez-Granger J, Navarro-Alarcon M, Gutierrez-Fernandez J . Activity of melatonin against Leishmania infantum promastigotes by mitochondrial dependent pathway. Chem Biol Interact. 2014; 220:84-93. DOI: 10.1016/j.cbi.2014.06.016. View

5.
Li J, Wang X, Wang L, Ying X, Ren X, Liu H . High in vitro antibacterial activity of Pac-525 against Porphyromonas gingivalis biofilms cultured on titanium. Biomed Res Int. 2015; 2015:909870. PMC: 4325973. DOI: 10.1155/2015/909870. View